Neurelis will host a 90-minute virtual investor call to highlight updates on two of its product candidates.

NRL-1004 for Acute Agitation – 10:30 am – 11:15 am ET

• NRL-1004, an investigational nasal spray formulation of olanzapine, which utilizes Neurelis proprietary Intravail®, technology, for the treatment of acute agitation, featuring Leslie Lucien Citrome, MD, MPH (New York Medical College, SUNY Upstate Medical University, Icahn School of Medicine at Mount Sinai).

NRL-1049 for Cerebral Cavernous Malformations – 11:15 am – 12:00 pm ET

• NRL-1049, an investigational, Phase 1 stage new chemical entity Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMs), featuring Issam Awad, MD, MSc, FACS, MA (University of Chicago Medicine) and Connie Lee, PsyD (Alliance to Cure Cavernous Malformation).

Both parts will include overviews of the disease state, unmet need, and current treatment landscape for patients, as well as a discussion of the potential differentiating features of Neurelis’ product candidates. A live question and answer session will follow the formal presentations of each Part 1 and 2.